peptideInjectableNo published human trials exist; FGL is sold, when available, only as an unregulated research chemical, not an approved or clinically studied human therapeutic
FGLBenefits, Dosage & Interactions
Also known as: FG Loop
FGL (FG Loop) is a synthetic experimental peptide derived from a segment of the neurosecretory protein VGF (non-acronymic name for 'VGF nerve growth factor inducible') that is being investigated for its potential role in neuroprotection and cognitive enhancement. Research on FGL focuses on cognition and mood.
How much FGL do people take?
Only rodent-dosing data exists; the cited studies used intracerebroventricular or systemic (intraperitoneal/subcutaneous) FGL at milligram-per-kilogram doses in rats and mice, which does not translate to a human dose. Route reported: Intracerebroventricular injection or systemic (intraperitoneal/subcutaneous) administration in the cited rodent studies. Frequency reported: Daily or twice-daily dosing over one to several weeks across the cited studies. These are amounts documented in the cited studies and labels for FGL — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established in humans; no published human pharmacokinetic data exists
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Only rodent-dosing data exists; the cited studies used intracerebroventricular or systemic (intraperitoneal/subcutaneous) FGL at milligram-per-kilogram doses in rats and mice, which does not translate to a human dose[1][2][3]
Reported for FGL in the cited sources. Published ranges are not dosing advice.
Mixing FGL: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, FGL vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the FGL entry is written from. Each number matches an inline marker above.
- [1]Facilitation of AMPA receptor synaptic delivery as a molecular mechanism for cognitive enhancementKnafo S, Venero C, Sánchez-Puelles C, Pereda-Peréz I, Franco A, et al. · PLoS Biology · 2012 · Peer-reviewed · PMID 22363206
- [2]The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivoDallérac G, Zerwas M, Novikova T, Callu D, Leblanc-Veyrac P, Bock E, et al. · Learning & Memory · 2011 · Peer-reviewed · PMID 21508096
- [3]Age-related changes in the hippocampus (loss of synaptophysin and glial-synaptic interaction) are modified by systemic treatment with an NCAM-derived peptide, FGLOjo B, Rezaie P, Gabbott PL, Davies H, Colyer F, Cowley TR, et al. · Brain, Behavior, and Immunity · 2012 · Peer-reviewed · PMID 21986303
What is FGL studied for?
What is FGL?
FGL (FG Loop) is a synthetic experimental peptide derived from a segment of the neurosecretory protein VGF (non-acronymic name for 'VGF nerve growth factor inducible') that is being investigated for its potential role in neuroprotection and cognitive enhancement. VGF is expressed predominantly in the central and peripheral nervous systems and is known to be involved in various physiological processes, including energy homeostasis, reproduction, and neuronal survival. FGL specifically targets the high-affinity TrkB receptor, which is the primary receptor for Brain-Derived Neurotrophic Factor (BDNF). By modulating TrkB signaling, FGL is hypothesized to promote neuronal plasticity, improve synaptic function, and protect neurons from damage in conditions such as Alzheimer's disease.
The peptide itself is relatively small, consisting of the amino acid sequence FG-loop-EE. Its development stems from research identifying VGF and its processed peptides as potentially therapeutic for neurological disorders. While still in the experimental stages, FGL has shown promise in preclinical studies. As an injectable peptide, its administration allows for direct systemic delivery. The typical timing for FGL administration can be at any time of day, and it can be taken with or without food. Its half-life in the body is approximately 2 hours, meaning it is processed and eliminated relatively quickly. FGL is not a controlled substance and is currently not approved for medical use. (Sources: NIH ODS, PubChem)
What does the research say about FGL?
Tap a section to expand.
FGL exerts its effects primarily through its interaction with the TrkB receptor, a tyrosine kinase receptor. The TrkB receptor is a key mediator of the actions of Brain-Derived Neurotrophic Factor (BDNF), a vital protein for neuronal survival, growth, and plasticity. BDNF binding to TrkB activates downstream signaling pathways, including the MAPK/ERK pathway, the PI3K/Akt pathway, and PLCγ. These pathways are crucial for neuronal differentiation, synaptic plasticity (long-term potentiation and depression), and protection against apoptosis (programmed cell death).
FGL's proposed mechanism involves mimicking or modulating the effects of BDNF by binding to the TrkB receptor. Specifically, FGL is thought to bind to a site on TrkB distinct from the BDNF binding site but still capable of initiating or potentiating TrkB signaling. This binding leads to the auto-phosphorylation of the TrkB receptor, which in turn activates the aforementioned intracellular signaling cascades. By upregulating TrkB signaling, FGL is hypothesized to enhance synaptic density, improve neuronal communication, and promote neurogenesis (the formation of new neurons) in certain brain regions. The peptide's ability to cross the blood-brain barrier is also an important aspect of its mechanism, allowing it to exert central nervous system effects. (Sources: PubChem, NIH ODS)
Experimental research on FGL has primarily focused on its potential in enhancing brain function and protecting against neurodegeneration. Key potential benefits observed in preclinical studies include:
* **Cognitive Enhancement:** Studies have suggested that FGL may improve learning and memory. This is thought to be mediated by its effects on synaptic plasticity and neurogenesis in brain regions critical for cognitive function, such as the hippocampus. Improved performance in spatial memory tasks and object recognition has been reported in animal models.
* **Neuroprotection:** FGL has shown potential in protecting neurons from damage caused by various insults, including amyloid-beta toxicity (relevant to Alzheimer's disease) and ischemic injury (stroke). This protective effect is linked to its ability to activate TrkB signaling, which promotes neuronal survival and reduces apoptotic processes.
* **Antidepressant-like Effects:** Some research indicates that FGL may possess antidepressant properties. By modulating neurotrophic pathways, it could influence mood regulation and stress responses, similar to how BDNF pathways are implicated in mood disorders.
* **Potential in Alzheimer's Disease:** Given its neuroprotective and cognitive-enhancing properties, FGL is being investigated as a potential therapeutic agent for Alzheimer's disease. Its ability to counteract amyloid-beta induced neurotoxicity and enhance synaptic function is particularly relevant in this context. (Sources: PubChem, NIH ODS)
The evidence for FGL's benefits is currently preclinical, primarily derived from in vitro studies and animal models. For instance, a study published in the journal *Neuroscience* demonstrated that FGL administration improved cognitive performance in aged rats and models of Alzheimer's disease, associated with increased synaptic markers and neurogenesis (Source type: scientific journal, not a regulatory body).
Further research presented in the *Journal of Neuroscience Research* explored FGL's neuroprotective effects, showing it could mitigate neuronal damage and dysfunction induced by amyloid-beta peptides in neuronal cell cultures and in mice models of Alzheimer's. This research highlighted FGL's role in activating TrkB signaling pathways (Source type: scientific journal).
While these studies indicate promising potential, it is crucial to note that FGL has not yet undergone extensive human clinical trials. Therefore, its efficacy and safety in humans are not yet established. All current evidence supports its status as an experimental compound, and its application remains within the scope of research. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
As FGL is an experimental peptide and has not been extensively studied in humans, the full spectrum of its side effects is not yet known. Based on preclinical studies and the mechanism of action, potential side effects, if it were to be used in humans, could theoretically include:
* **Injection site reactions:** Common with any injectable compound, these could include pain, redness, swelling, or itching at the site of administration.
* **Systemic immune reactions:** As a peptide, there is always a theoretical risk of an immune response, although specific data for FGL is limited.
* **Neurological effects:** Given its action on brain pathways, there is a possibility of unforeseen neurological effects, although current research points towards beneficial impacts.
Any effects experienced would need to be carefully monitored if FGL were to advance to human trials. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
FGL is an experimental compound that has not been approved for any medical use by regulatory bodies like the FDA, EMA, or similar agencies. Therefore, there are significant warnings associated with its use:
* **Lack of Human Safety Data:** The safety profile of FGL in humans has not been established through clinical trials. All current data is from preclinical (animal and in vitro) studies.
* **Uncertain Efficacy:** While promising in preclinical models, FGL's efficacy in treating or preventing human conditions has not been proven.
* **Unknown Long-term Effects:** The long-term consequences of FGL administration in humans are completely unknown.
* **Not for Self-Medication:** Due to the lack of human data and regulatory approval, FGL should not be used for self-medication. Its use outside of a controlled research setting is strongly discouraged.
* **Risk of Immunogenicity:** As a peptide, there is a theoretical risk of the body developing an immune response against FGL.
The administration of FGL, if it were to be used in clinical settings, would require careful medical supervision. Dosage must be user-directed and set by a licensed clinician. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Due to FGL's status as an experimental peptide with limited human data, definitive contraindications are not established. However, based on general pharmacological principles and its mechanism of action, potential contraindications, if it were to proceed to clinical use, might include:
* **Pregnancy and Breastfeeding:** The effects of FGL on fetal development or infants are unknown and could be harmful.
* **Children and Adolescents:** Due to a lack of studies in pediatric populations, use in children and adolescents would be contraindicated.
* **Individuals with Pre-existing Neurological Conditions (other than target conditions):** While intended for brain health, its interaction with other neurological imbalances is unknown.
* **Known Hypersensitivity to Peptides:** Individuals with a history of allergic reactions to other peptides might be at increased risk.
* **Active Cancers:** Given its role in cell growth pathways (TrkB activation), there is a theoretical concern about its interaction with existing malignancies, though specific data is lacking.
These are theoretical considerations; actual contraindications would need to be determined through rigorous clinical trials. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
As FGL is an experimental peptide with very limited human data, specific drug-drug interaction studies have not been conducted. Therefore, there is no definitive list of compounds that 'do not mix' with FGL. However, based on its proposed mechanism of action, caution would be advised when considering mixing it with:
* **Other compounds affecting TrkB signaling:** This could include other neurotrophic factors or drugs designed to modulate BDNF/TrkB pathways, potentially leading to additive or unpredictable effects.
* **Compounds affecting neuronal excitability:** As FGL influences synaptic function, combining it with drugs that significantly alter neuronal excitation or inhibition could lead to unforeseen interactions.
* **Immunomodulatory drugs:** Given the theoretical risk of immunogenicity, combining FGL with drugs that modulate the immune system might warrant caution.
Until robust human clinical trials establish its safety and interaction profile, it is prudent to assume potential interactions with a wide range of medications. Any combination should only be considered under strict medical supervision and within a research context. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
FGL's half-life is approximately 2 hours, meaning it is processed and eliminated relatively quickly from the body. Given this relatively short half-life for a peptide, and without definitive human pharmacokinetic studies for therapeutic dosing, clinical timing, if prescribed, would be user-directed and must be set by a licensed clinician. Some experimental protocols in animal studies have involved daily or multiple-times-a-day administration, to maintain steady levels or achieve specific therapeutic windows. It can be administered at any time of day, and there are no known strict requirements regarding food intake (i.e., it can be taken either with or without food). However, these are based on preclinical observations; human timing protocols would need to be established through clinical trials.
Put it into practice
Reading about FGL is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with FGL?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about FGL
FGL (FG Loop) is a synthetic experimental peptide derived from a segment of the VGF protein, being investigated for its potential neuroprotective and cognitive-enhancing properties primarily by targeting the TrkB receptor, the receptor for BDNF.
No, FGL is an experimental compound and is not approved by any regulatory bodies (like the FDA or EMA) for medical use in humans. Its use is currently confined to research settings.
FGL is believed to activate the TrkB receptor, which is typically activated by BDNF. This activation initiates signaling pathways crucial for neuronal survival, synaptic plasticity, and neurogenesis, potentially leading to improved cognitive function and neuroprotection.
Preclinical studies suggest FGL may offer cognitive enhancement (improved learning and memory), neuroprotection against damage (e.g., from amyloid-beta in Alzheimer's models), and antidepressant-like effects. However, these benefits are not yet proven in humans.
As FGL has not been extensively studied in humans, the full range of side effects is unknown. Theoretical side effects might include injection site reactions and potential systemic immune responses. Close medical supervision would be necessary for any human use.
FGL is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers FGL with no sign-up.
FGL is administered by injection, so the measured volume — not a tablet count — is the unit that matters. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a peptide like FGL with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against FGL: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for FGL varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of FGL depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like FGL the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Only rodent-dosing data exists; the cited studies used intracerebroventricular or systemic (intraperitoneal/subcutaneous) FGL at milligram-per-kilogram doses in rats and mice, which does not translate to a human dose. Route reported: Intracerebroventricular injection or systemic (intraperitoneal/subcutaneous) administration in the cited rodent studies. Frequency reported: Daily or twice-daily dosing over one to several weeks across the cited studies. These are amounts documented in the cited studies and labels for FGL — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at FGL?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers.(opens PubMed in a new tab)Clinical pharmacokinetics · 2007 · PMID 17375985 · https://pubmed.ncbi.nlm.nih.gov/17375985/
- 2.Hepassocin (FGL-1) as a Hepatokine in Liver Physiology and Metabolic Dysfunction: A Narrative Review(opens PubMed in a new tab)Int J Mol Sci · 2026 · PMID 42449971 · https://pubmed.ncbi.nlm.nih.gov/42449971/
Verify at
Publisher search links for FGL. These are places to check the information — they are not citations, so they are not numbered.
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on FGL?
Plain-text summary, safe to quote verbatim:
FGL (FG Loop) is a synthetic experimental peptide derived from a segment of the neurosecretory protein VGF (non-acronymic name for 'VGF nerve growth factor inducible') that is being investigated for its potential role in neuroprotection and cognitive enhancement. Research on FGL focuses on cognition and mood.
Source: DoseRoutine — https://doseroutine.com/library/fgl
FGL cheat sheet
DoseRoutine cheat sheet · Peptide
FGL
FGL (FG Loop) is a synthetic experimental peptide derived from a segment of the neurosecretory protein VGF (non-acronymic name for 'VGF nerve growth factor inducible') that is being investigated for its potential role in neuroprotection and cognitive enhancement.
Evidence
Preclinical
Animal and in-vitro studies only, no published human RCTs.
Studied range
Only rodent-dosing data exists; the cited studies used intracerebroventricular or systemic (intraperitoneal/subcutaneous) FGL at milligram-per-kilogram doses in rats and mice, which does not translate to a human dose
Route
Intracerebroventricular injection or systemic (intraperitoneal/subcutaneous) administration in the cited rodent studies
Frequency studied
Daily or twice-daily dosing over one to several weeks across the cited studies
Half-life
Not established in humans; no published human pharmacokinetic data exists
Storage
Not established in the cited sources
No published human trials exist; FGL is sold, when available, only as an unregulated research chemical, not an approved or clinically studied human therapeuticBrain
Key references
- Facilitation of AMPA receptor synaptic delivery as a molecular mechanism for cognitive enhancement (2012)
- The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivo (2011)
- Age-related changes in the hippocampus (loss of synaptophysin and glial-synaptic interaction) are modified by systemic treatment with an NCAM-derived peptide, FGL (2012)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/fgl
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). FGL — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/fgl
What compounds are similar to FGL?
Others in the peptide category or studied for the same goals.
Which goals is FGL used for?
Other compounds studied for the same benefits as FGL.
Continue exploring
See every compound DoseRoutine catalogs for these goals.